<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective AnalysisJustin F. Gainor, Mari Mino–Kenudson, Christopher G. Azzoli et al.|Clinical Cancer Research|2016Cited by 1.2k
Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung CancerLecia V. Sequist, D. Ross Camidge, Jean‐Charles Soria et al.|New England Journal of Medicine|2015Cited by 664